Comparative Pharmacology
Head-to-head clinical analysis: ALEVE PM versus CHILDREN S ELIXSURE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ALEVE PM versus CHILDREN S ELIXSURE.
ALEVE PM vs CHILDREN'S ELIXSURE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Diphenhydramine is a histamine H1 receptor antagonist that competes with histamine for binding at H1 receptor sites, reducing symptoms of allergic reactions and causing sedation. Naproxen is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX) enzymes, decreasing synthesis of prostaglandins, which reduces pain and inflammation.
Acetaminophen: weakly inhibits cyclooxygenase (COX) in central nervous system, reduces prostaglandin synthesis, elevates pain threshold, and acts on hypothalamic heat-regulating center to lower body temperature. Chlorpheniramine: first-generation antihistamine; competitively antagonizes histamine at H1 receptors, reducing allergic symptoms. Dextromethorphan: noncompetitive NMDA receptor antagonist and sigma-1 agonist; suppresses cough by elevating threshold in medullary cough center. Pseudoephedrine: indirectly acting sympathomimetic; releases norepinephrine from presynaptic terminals, causing vasoconstriction and nasal decongestion.
1 tablet (220 mg naproxen sodium / 25 mg diphenhydramine HCl) orally at bedtime as needed. Maximum: 2 tablets in 24 hours.
No established adult dose; product is specifically indicated for pediatric use only. Not recommended for adults.
None Documented
None Documented
Naproxen: 12-17 hours (mean 13.6 hours); sufficient for twice-daily dosing; prolonged in renal impairment. Diphenhydramine: 2.4-9.3 hours (mean 5.5 hours); longer in elderly, hepatic impairment.
Terminal half-life: 4–6 hours in children with normal hepatic function; prolonged to >8 hours in hepatic impairment or overdose.
Naproxen: renal (95% as unchanged drug and metabolites, primarily as naproxen and 6-O-desmethyl naproxen). Diphenhydramine: renal (50-60% as unchanged drug and metabolites, primarily as diphenhydramine and nor diphenhydramine); small amounts in feces.
Renal elimination: ~90% as unchanged drug and active metabolite paracetamol glucuronide/sulfate conjugates; biliary/fecal: <5%.
Category C
Category C
NSAID/Antihistamine Combination
NSAID